Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10898 |
Samuraciclib hydrochloride
ICEC0942 hydrochloride,CT7001 hydrochloride |
Apoptosis; CDK | Apoptosis; Cell Cycle/Checkpoint |
Samuraciclib hydrochloride (ICEC0942 hydrochloride) 是一种具有选择性,ATP 竞争性和口服活性的CDK7抑制剂,IC50为 41 nM。它以 GI50值为 0.2-0.3 µM 来抑制乳腺癌细胞系的生长,具有抗肿瘤作用。 | |||
T63650 | Samuraciclib hydrochloride hydrate | ||
Samuraciclib (CT7001) hydrochloride hydrate 是有效的、选择性、ATP 竞争性的、口服具有活力的 CDK7 抑制剂 (IC50: 41 nM)。Samuraciclib hydrochloride hydrate 对 CDK7的选择性分别是 CDK1,CDK2 (IC50为 578 nM),CDK5 和 CDK9 的 45 倍,15 倍,230 倍和 30 倍。Samuraciclib hydrochloride hydrate 能够抑制乳腺癌细胞系的生长 (GI50: 0.2-0.3 μM),表现出有效的抗肿瘤效果。 | |||
T35650 | Samuraciclib trihydrochloride | ||
Samuraciclib (CT7001) trihydrochloride is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib trihydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib trihydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib trihydrochloride has anti-tumor effects[1][2]. | |||
T61835 |
Samuraciclib
|
||
Samuraciclib (CT7001) is a potent, selective, and orally active inhibitor of CDK7, with an ATP-competitive nature. It effectively inhibits CDK7 with an IC 50 value of 41 nM. Furthermore, Samuraciclib demonstrates remarkable selectivity ratios, with 45-fold, 15-fold, 230-fold, and 30-fold selectivity over CDK1, CDK2 (IC 50 of 578 nM), CDK5, and CDK9, respectively. Notably, Samuraciclib has been found to inhibit the growth of breast cancer cell lines, exhibiting GI 50 values ranging between 0.2-0.... |